For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an incr ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Compounded GLP-1s helped people continue treatment while brand-name GLP-1 injections were in shortage. But they’re not meant to be a long-term solution when FDA-approved options are available.

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

GLP-1RA use, but not SGLT2i or pioglitazone use, was associated with a statistically significant lower risk for dementia and cognitive impairment.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

Asked how this intervention might compare with drugs in development to mitigate muscle loss with GLP-1 RA therapy, Peralta-Reich said “while we are optimistic we are not applying the results of ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.